Phase I/II Study of GDC-7035 in Advanced Solid Tumors with KRAS G12D Mutation
Genentech is conducting a first-in-human Phase I/II study of GDC-7035 targeting KRAS G12D mutations in advanced solid tumors.
Phase I
Oncology / KRAS Inhibitor
Status
Active
Sponsor
Roche
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing Phase I/II study of GDC-7035 by Genentech is significant as it targets the KRAS G12D mutation, a critical area in oncology. Success in this trial could solidify Genentech's position in the competitive landscape of KRAS inhibitors, impacting their overall portfolio and market strategy.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial progress, safety data, and preliminary efficacy results as they become available.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.